Home  |  Contact

UniProtKB/Swiss-Prot P13051: Variant p.Phe251Ser

Uracil-DNA glycosylase
Gene: UNG
Variant information

Variant position:  251
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Phenylalanine (F) to Serine (S) at position 251 (F251S, p.Phe251Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (F) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In HIGM5; fully active and stable when expressed in E.coli; mistargeted to mitochondria rather than the nucleus.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  251
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  313
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         WEQFTDAVVSWLNQN-S---NGLVFLLWGSYAQK----------KGSAIDRKRHH

Mouse                         WEQFTDAVVSWLNQN-L---SGLVFLLWGSYAQK-------

Caenorhabditis elegans        WQTFTDTVIRIISRQSE---KPIVFLLWGGFAHK-------

Slime mold                    WADFTDAVLKILSKQ-D---QPIVFILWGGFAQK-------


Fission yeast                 WETFTSAVLQVALNRNR---KGLVILAWGTPAAK-------

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 313 Uracil-DNA glycosylase
Beta strand 250 – 255

Literature citations

Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination.
Imai K.; Slupphaug G.; Lee W.-I.; Revy P.; Nonoyama S.; Catalan N.; Yel L.; Forveille M.; Kavli B.; Krokan H.E.; Ochs H.D.; Fischer A.; Durandy A.;
Nat. Immunol. 4:1023-1028(2003)
Cited for: VARIANT HIGM5 SER-251;

B cells from hyper-IgM patients carrying UNG mutations lack ability to remove uracil from ssDNA and have elevated genomic uracil.
Kavli B.; Andersen S.; Otterlei M.; Liabakk N.B.; Imai K.; Fischer A.; Durandy A.; Krokan H.E.; Slupphaug G.;
J. Exp. Med. 201:2011-2021(2005)

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.